IFITM3 and AL amyloidosis: Interestingly, platelets from patients with multiple myeloma or myeloproliferative disorders had significantly increased IFITM3 expression (Supplemental Figure 24), suggesting IFITM3 may also promote thrombotic complications in these patients: a hypothesis to be tested in future studies.